This is a correction document to the commentary "Beyond integrase: the rise of doravirine and islatravir in the management of HIV" by Estrada V and Cabello-Clotet N, published in Lancet 2026; 407: 551–53. In the sixth paragraph of the comment, the second sentence was updated. The new wording reads: "Both studies excluded participants with prior virologic failure, documented NNRTI resistance associated with doravirine resistance, or active hepatitis B virus infection." This correction was made in the online version on March 5, 2026. The document does not contain additional details about the original comment or the studies.